Streetbeat News

Regulatory

COIN

Cryptocurrency firms, led by Coinbase, are heavily investing in the 2024 U.S. presidential election, with a record $1.5 billion in donations. This marks a strategic move to influence regulatory policies affecting digital assets.

Portfolio Pulse from Murtuza Merchant

August 27, 2024 | 12:00 pm

BUSE

Trading for a certain asset was halted at 7:55:00 a.m. ET due to pending news. This indicates that significant information is expected to be released, which could impact the asset's price once trading resumes.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 11:55 am

ARAY

Accuray has received the CE Mark for its Accuray Helix, a CT-guided helical radiotherapy system. This system targets emerging markets with limited access to advanced cancer care.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 11:50 am

AROC

Archrock announced the expiration of the HSR waiting period for its acquisition of Total Operations and Production Services, LLC. The deal is expected to close in Q3 2024, pending customary conditions.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 11:47 am

CSCI

COSCIENS Biopharma announced that initial analysis of their study results suggests a high false positive rate in comparator tests, affecting macimorelin's ability to meet the primary efficacy endpoint.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 11:33 am

CSCI

Trading for CSCI has been halted as of 7:25 a.m. ET due to pending news. This indicates that significant information regarding the company is expected to be released soon, which could impact its stock price.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 11:25 am

LZM

Lifezone Metals has started the risk insurance process with the U.S. Development Finance Corporation for its nickel project in Tanzania. This move is aimed at mitigating potential risks associated with the project.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 11:06 am

OKYO

OKYO Pharma has secured a US patent for OK-101, a novel drug candidate for treating dry eye disease. OK-101 is a lipid conjugated chemerin peptide agonist targeting the ChemR23 receptor on immune cells in the eye, aiming to address inflammatory responses.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 11:01 am

BSX

Boston Scientific has received the CE Mark for its ACURATE Prime Aortic Valve System, a new transcatheter aortic valve replacement technology. This addition enhances their structural heart portfolio.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 10:59 am

MRK

Merck has started a Phase 3 trial named Shorespan-007 for Bomedemstat, targeting essential thrombocythemia patients who have not previously received cytoreductive therapy.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 10:49 am